0001104659-23-082726.txt : 20230720 0001104659-23-082726.hdr.sgml : 20230720 20230720161700 ACCESSION NUMBER: 0001104659-23-082726 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230718 FILED AS OF DATE: 20230720 DATE AS OF CHANGE: 20230720 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kemble George CENTRAL INDEX KEY: 0001858176 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41742 FILM NUMBER: 231099911 MAIL ADDRESS: STREET 1: SAGIMET BIOSCIENCES INC. STREET 2: 155 BOVET RD., STE. 303 CITY: SAN MATEO STATE: CA ZIP: 94402 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sagimet Biosciences Inc. CENTRAL INDEX KEY: 0001400118 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205991472 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 155 BOVET RD., SUITE 303 CITY: SAN MATEO STATE: CA ZIP: 94402 BUSINESS PHONE: (650) 561-8600 MAIL ADDRESS: STREET 1: 155 BOVET RD., SUITE 303 CITY: SAN MATEO STATE: CA ZIP: 94402 FORMER COMPANY: FORMER CONFORMED NAME: 3-V Biosciences, Inc. DATE OF NAME CHANGE: 20070521 4 1 tm2321276-16_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-07-18 0 0001400118 Sagimet Biosciences Inc. SGMT 0001858176 Kemble George SAGIMET BIOSCIENCES INC. 155 BOVET RD., SUITE 303 SAN MATEO CA 94402 1 0 0 0 0 Stock Option (Right to Buy) 0.79 2023-07-18 4 D 0 5630 0 D 2023-09-26 Common Stock 5630 0 D Stock Option (Right to Buy) 0.79 2023-07-18 4 A 0 5630 0 A 2023-09-26 Series A Common Stock 5630 5630 D Stock Option (Right to Buy) 11.13 2023-07-18 4 D 0 3179 0 D 2024-03-12 Common Stock 3179 0 D Stock Option (Right to Buy) 11.13 2023-07-18 4 A 0 3179 0 A 2024-03-12 Series A Common Stock 3179 3179 D Stock Option (Right to Buy) 23.05 2023-07-18 4 D 0 7147 0 D 2024-12-16 Common Stock 7147 0 D Stock Option (Right to Buy) 23.05 2023-07-18 4 A 0 7147 0 A 2024-12-16 Series A Common Stock 7147 7147 D Stock Option (Right to Buy) 19.87 2023-07-18 4 D 0 26352 0 D 2025-10-12 Common Stock 26352 0 D Stock Option (Right to Buy) 19.87 2023-07-18 4 A 0 26352 0 A 2025-10-12 Series A Common Stock 26352 26352 D Stock Option (Right to Buy) 6.36 2023-07-18 4 D 0 367824 0 D 2029-04-27 Common Stock 367824 0 D Stock Option (Right to Buy) 6.36 2023-07-18 4 A 0 367824 0 A 2029-04-27 Series A Common Stock 367824 367824 D Stock Option (Right to Buy) 6.36 2023-07-18 4 D 0 46432 0 D 2029-04-27 Common Stock 46432 0 D Stock Option (Right to Buy) 6.36 2023-07-18 4 A 0 46432 0 A 2029-04-27 Series A Common Stock 46432 46432 D Stock Option (Right to Buy) 6.36 2023-07-18 4 D 0 526332 0 D 2031-01-26 Common Stock 526332 0 D Stock Option (Right to Buy) 6.36 2023-07-18 4 A 0 526332 0 A 2031-01-26 Series A Common Stock 526332 526332 D Stock Option (Right to Buy) 7.15 2023-07-18 4 D 0 21173 0 D 2032-10-16 Common Stock 21173 0 D Stock Option (Right to Buy) 7.15 2023-07-18 4 A 0 21173 0 A 2032-10-16 Series A Common Stock 21173 21173 D Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. This option is fully vested and exercisable as of the date hereof. The shares underlying this option vest and become exercisable in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date. 25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. /s/ Dennis Hom, Attorney-in-Fact 2023-07-20